Peplin, Inc. has announced the initiation of its second non-head Phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel for the treatment of actinic (solar) ...

Peplin, Inc today announced a merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical care, will acquire all outstanding ...

Shares in cancer researcher Peplin Biotech Ltd fell almost 27 per cent in late trading Monday after the company said it would discontinue its collaboration with Allergan Inc for the development of a ...

Peplin’s lead product candidate, PEP005 Gel is currently in Phase 3 clinical trials for actinic (solar) keratosis (AK), a common pre-cancerous skin lesion, on both head and non-head locations. Peplin ...

EMERYVILLE, Calif. and BRISBANE, Australia, December 16, 2008--Peplin, Inc. (ASX:PLI) today announced the completion of enrolment of its 250 patient pivotal Phase III US and Australian clinical trial ...

Company will gain a late-stage compound for the treatment of actinic keratosis. LEO Pharma has agreed to acquire Peplin for roughly $287.5 million in cash, or roughly A$342.20. Additionally, LEO will ...

After scrapping plans for an initial public offering on Nasdaq, Australian-listed specialty dermatology company Peplin Inc. plans to raise $24 million in a private placement of stock and warrants. The ...

AUSTRALIAN skin cancer researcher Peplin is returning to its shareholders for a third time to get approval to launch on the Nasdaq, but this time it is a step closer, announcing investment firm MPM ...

Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will ...